iTeos Therapeutics, Inc. $ITOS Shares Acquired by RA Capital Management L.P.

Key Points

• RA Capital Management L.P. increased its stake in iTeos Therapeutics by 74.4% during the first quarter, acquiring a total of approximately 3.65 million shares worth $21.78 million.
• Recent analyst ratings for iTeos Therapeutics include lowered ratings from HC Wainwright and JPMorgan Chase & Co., with price targets now set between $8.00 and $15.50.
• Insider transactions show that both the CEO and a director sold shares recently, with a total of 277,185 shares sold by insiders over the past 90 days.

RA Capital Management L.P. raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 74.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,649,057 shares of the company's stock after purchasing an additional 1,556,798 shares during the period. RA Capital Management L.P. owned 9.53% of iTeos Therapeutics worth $21,785,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of iTeos Therapeutics during the fourth quarter worth approximately $42,000. CWM LLC grew its position in shares of iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after acquiring an additional 6,936 shares during the last quarter. Paloma Partners Management Co purchased a new position in shares of iTeos Therapeutics during the first quarter worth approximately $65,000. Forefront Analytics LLC purchased a new position in shares of iTeos Therapeutics during the fourth quarter worth approximately $85,000. Finally, Graham Capital Management L.P. purchased a new position in shares of iTeos Therapeutics during the fourth quarter worth approximately $85,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other iTeos Therapeutics news, CEO Michel Detheux sold 43,883 shares of the firm's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the sale, the chief executive officer owned 153,903 shares of the company's stock, valued at approximately $1,542,108.06. This trade represents a 22.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 96,165 shares of company stock valued at $964,096 over the last three months. 14.20% of the stock is currently owned by company insiders.

iTeos Therapeutics Price Performance

iTeos Therapeutics stock remained flat at $10.15 during midday trading on Friday. iTeos Therapeutics, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $17.63. The business has a fifty day simple moving average of $10.15 and a two-hundred day simple moving average of $8.52. The company has a market cap of $448.73 million, a price-to-earnings ratio of -2.17 and a beta of 1.31.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.51) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.39). As a group, analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wedbush restated an "outperform" rating and set a $10.50 target price (down from $12.00) on shares of iTeos Therapeutics in a research report on Monday, July 21st. Wall Street Zen upgraded shares of iTeos Therapeutics to a "sell" rating in a research report on Saturday, August 30th. Raymond James Financial set a $12.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Wells Fargo & Company lowered their price objective on shares of iTeos Therapeutics from $12.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Finally, Leerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $15.50.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.